KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Amneal Pharmaceuticals (AMRX) Other Gross PP&E Adjustments (2017 - 2026)

Amneal Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 9 years, most recently at $988.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 6.43% year-over-year to $988.4 million; the TTM value through Dec 2025 reached $988.4 million, up 6.43%, while the annual FY2025 figure was $988.4 million, 6.43% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $988.4 million at Amneal Pharmaceuticals, up from -$54.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $988.4 million in Q4 2025 and troughed at -$184.3 million in Q1 2023.
  • A 5-year average of $144.7 million and a median of -$96.4 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: crashed 151.63% in 2022 and later soared 83.74% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $842.8 million in 2021, then increased by 1.32% to $853.9 million in 2022, then rose by 5.12% to $897.6 million in 2023, then grew by 3.46% to $928.7 million in 2024, then rose by 6.43% to $988.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for AMRX at $988.4 million in Q4 2025, -$54.4 million in Q3 2025, and -$17.7 million in Q2 2025.